Comprehensive molecular profiling of lung adenocarcinoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Adenocarcinoma of the lung is the leading cause of cancer death worldwide. Here we report molecular profiling of 230 resected lung adenocarcinomas using messenger RNA, microRNA and DNA sequencing integrated with copy number, methylation and proteomic analyses. High rates of somatic mutation were seen (mean 8.9 mutations per megabase). Eighteen genes were statistically significantly mutated, including RIT1 activating mutations and newly described loss-of-function MGA mutations which are mutually exclusive with focal MYC amplification. EGFR mutations were more frequent in female patients, whereas mutations in RBM10 were more common in males. Aberrations in NF1, MET, ERBB2 and RIT1 occurred in 13% of cases and were enriched in samples otherwise lacking an activated oncogene, suggesting a driver role for these events in certain tumours. DNA and mRNA sequence from the same tumour highlighted splicing alterations driven by somatic genomic changes, including exon 14 skipping in MET mRNA in 4% of cases. MAPK and PI(3)K pathway activity, when measured at the protein level, was explained by known mutations in only a fraction of cases, suggesting additional, unexplained mechanisms of pathway activation. These data establish a foundation for classification and further investigations of lung adenocarcinoma molecular pathogenesis. An integrated transcriptome, genome, methylome and proteome analysis of over 200 lung adenocarcinomas reveals high rates of somatic mutations, 18 statistically significantly mutated genes including RIT1 and MGA, splicing changes, and alterations in MAPK and PI(3)K pathway activity. This report from The Cancer Genome Atlas Research Network presents molecular profiling of 230 resected untreated lung adenocarcinomas. Integrated analyses of transcriptome, genome, methylome and proteome collectively identify high rates of somatic mutation, significantly mutated genes including RIT1 and MGA, splicing alterations driven by somatic genomic changes, and point to as yet unidentified lesions that alter MAPK and PI(3)K pathway activity. These data establish a foundation for classification and further investigations of the leading cause of cancer death worldwide.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Landmark large scale sequencing studies have established a census of major KRAS co-mutations in both early-stage and advanced LUAD15, 34, 59, 62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Mutations in PIK3CA and CTNNB1 are more frequent in advanced stage tumors compared with early stage LUADs, pointing towards functional roles in malignant progression and metastasis, whereas alterations in TP53 (62.5%), RB1 (9.5 −12.5%) and NKX2–1 (12.5%) appear to occur with comparable frequencies in early- and advanced-stage tumors15, 34, 72, 73.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“earlier studies that identified a central role for WNT signaling in LUAD metastasis”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Inactivating mutations or loss of STK11/LKB1, which define one of the major genomic sub-groups of KRAS-mutant lung cancers1,19,62, are of particular interest because they are associated with decreased responsiveness to immune checkpoint blockade9,63 and poor overall prognosis64.”
From LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers (2025) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Importantly, large-scale profiling studies utilizing either whole exome sequencing or broad targeted sequencing panels in NSCLC tumors have revealed multiple non-random patterns of co-occurring or mutually exclusive mutations, which typically vary depending on the particular oncogenic driver mutation15, 34, 58–62.”
From Co-occurring genomic alterations in non-small-cell lung cancer biology and therapy (2019) · cites this paper as [34]
12 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationMutational heterogeneity in cancer and the search for new cancer-associated genes
Lawrence, M. S., Stojanov, P., Polak, P., Kryukov, G. V., Cibulskis, K., Sivachenko, A., Carter, S. L., Stewart, C., Mermel, C. H., Roberts, S. A., et al. (2013) · Nature · doi:10.1038/nature12213 · Cited by 5,461
Self-citationSensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981
Travis, W. D., Brambilla, E., Noguchi, M., Nicholson, A. G., Geisinger, K. R., Yatabe, Y., Beer, D. G., Powell, C. A., Riely, G. J., Van Schil, P. E., et al. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318206a221 · Cited by 4,792
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y.-J., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S.-H. I., Dezube, B. J., Jänne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,446 · cited 1×
“Analysis of mutations in PIK3CA and STK11, STK11 protein levels, and AMPK and AKT phosphorylation(33) led to the identification of three major mTOR patterns in lung adenocarcinoma: (1) tumours with minimal or basal mTOR pathway activation, (2) tumours showing higher mTOR activity accompanied by either STK11-inactivati…”
BackgroundComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Discovery and saturation analysis of cancer genes across 21 tumour types
Lawrence, M. S., Stojanov, P., Mermel, C. H., Robinson, J. T., Garraway, L. A., Golub, T. R., Meyerson, M., Gabriel, S. B., Lander, E. S., & Getz, G. (2014) · Nature · doi:10.1038/nature12912 · Cited by 3,096
Somatic mutations affect key pathways in lung adenocarcinoma
Ding, L., Getz, G., Wheeler, D. A., Mardis, E. R., McLellan, M. D., Cibulskis, K., Sougnez, C., Greulich, H., Muzny, D. M., Morgan, M. B., et al. (2008) · Nature · doi:10.1038/nature07423 · Cited by 2,681
Self-citationBhattacharjee, A., Richards, W. G., Staunton, J., Li, C., Monti, S., Vasa, P., Ladd, C., Beheshti, J., Bueno, R., Gillette, M., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191502998 · Cited by 2,576
Massive genomic rearrangement acquired in a single catastrophic event during cancer development
Stephens, P. J., Greenman, C. D., Fu, B., Yang, F., Bignell, G. R., Mudie, L. J., Pleasance, E. D., Lau, K. W., Beare, D., Stebbings, L. A., et al. (2011) · Cell · doi:10.1016/j.cell.2010.11.055 · Cited by 2,414
Cited by
Items 1,001–1,045 of 1,045
Costa, D. B. (2016) · Translational Lung Cancer Research · doi:10.21037/tlcr.2016.06.04 · Cited by 71
Theard, P. L., Sheffels, E., Sealover, N. E., Linke, A. J., Pratico, D. J., & Kortum, R. L. (2020) · eLife · doi:10.7554/elife.58204 · Cited by 69
Real-world deployment of a fine-tuned pathology foundation model for lung cancer biomarker detection
Campanella, G., Kumar, N., Nanda, S., Singi, S., Fluder, E., Kwan, R., Muehlstedt, S., Pfarr, N., Schüffler, P. J., Häggström, I., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03780-x · Cited by 69
Jiang, W., Wei, K., Pan, C., Li, H., Cao, J., Han, X., Tang, Y., Zhu, S., Yuan, W., He, Y., et al. (2018) · Cell Proliferation · doi:10.1111/cpr.12502 · Cited by 67
Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer
Li, S., Liu, S., Deng, J., Akbay, E. A., Hai, J., Ambrogio, C., Zhang, L., Zhou, F., Jenkins, R. W., Adeegbe, D. O., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3438 · Cited by 67
“2), and KRAS is mutated in approximately 30% of lung adenocarcinomas (3).”
BackgroundUncovering Prognosis-Related Genes and Pathways by Multi-Omics Analysis in Lung Cancer
Asada, K., Kobayashi, K., Joutard, S., Tubaki, M., Takahashi, S., Takasawa, K., Komatsu, M., Kaneko, S., Sese, J., & Hamamoto, R. (2020) · Biomolecules · doi:10.3390/biom10040524 · Cited by 67
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65
Brain high-throughput multi-omics data reveal molecular heterogeneity in Alzheimer’s disease
Eteleeb, A. M., Novotny, B. C., Tarraga, C. S., Sohn, C., Dhungel, E., Brase, L., Nallapu, A., Buss, J., Farias, F., Bergmann, K., et al. (2024) · PLOS Biology · doi:10.1371/journal.pbio.3002607 · Cited by 64
LKB1 inactivation modulates chromatin accessibility to drive metastatic progression
Pierce, S. E., Granja, J. M., Corces, M. R., Brady, J. J., Tsai, M. K., Pierce, A. B., Tang, R., Chu, P., Feldser, D. M., Chang, H. Y., et al. (2021) · Nature Cell Biology · doi:10.1038/s41556-021-00728-4 · Cited by 59
Han, H., Li, S., Chen, T., Fitzgerald, M., Liu, S., Peng, C., Tang, K. H., Cao, S., Chouitar, J., Wu, J., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-21-1526 · Cited by 57
Self-citationMetabolic features of cancer cells in NRF2 addiction status
Okazaki, K., Papagiannakopoulos, T., & Motohashi, H. (2020) · Biophysical Reviews · doi:10.1007/s12551-020-00659-8 · Cited by 57
“The aberrant activation of NRF2 is found in various cancers including the lung, gallbladder, esophagus, breast, head and neck, and renal cancers (Shibata et al. 2008; Wang et al. 2010; Shibata et al. 2011; Inoue et al. 2012; Onodera et al. 2014; Kanamori et al. 2015; Martinez et al. 2015; Cancer Genome Atlas Research…”
The effect of HMGB1 on the clinicopathological and prognostic features of non-small cell lung cancer
Feng, A., Tu, Z., & Yin, B. (2016) · Oncotarget · doi:10.18632/oncotarget.7050 · Cited by 57
Liang, S.-Q., Bührer, E. D., Berezowska, S., Marti, T. M., Xu, D., Froment, L., Yang, H., Hall, S. R. R., Vassella, E., Yang, Z., et al. (2019) · Oncogene · doi:10.1038/s41388-018-0479-6 · Cited by 55
Selective targeting of KRAS oncogenic alleles by CRISPR/Cas9 inhibits proliferation of cancer cells
Lee, W., Lee, J. H., Jun, S., Lee, J. H., & Bang, D. (2018) · Scientific Reports · doi:10.1038/s41598-018-30205-2 · Cited by 53
Self-citationDistinct Nrf2 Signaling Thresholds Mediate Lung Tumor Initiation and Progression
DeBlasi, J. M., Falzone, A., Caldwell, S., Prieto-Farigua, N., Prigge, J. R., Schmidt, E. E., Chio, I. I. C., Karreth, F. A., & DeNicola, G. M. (2023) · Cancer Research · doi:10.1158/0008-5472.can-22-3848 · Cited by 49
“mutations in the KEAP1-NRF2 pathway are found in up to 30% of cases (11, 12).”
MEK inhibitors block growth of lung tumours with mutations in ataxia–telangiectasia mutated
Smida, M., Fece de la Cruz, F., Kerzendorfer, C., Uras, I. Z., Mair, B., Mazouzi, A., Suchankova, T., Konopka, T., Katz, A. M., Paz, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms13701 · Cited by 44
Shee, K., Wells, J. D., Jiang, A., & Miller, T. W. (2019) · PLOS ONE · doi:10.1371/journal.pone.0224267 · Cited by 43
Gong, Z., Jia, Q., Chen, J., Diao, X., Gao, J., Wang, X., & Zhu, B. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.024 · Cited by 43
Self-citationJohnson, R. M., Qu, X., Lin, C.-F., Huw, L.-Y., Venkatanarayan, A., Sokol, E., Ou, F.-S., Ihuegbu, N., Zill, O. A., Kabbarah, O., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33172-5 · Cited by 42
Jakobsen, J. N., Santoni-Rugiu, E., Grauslund, M., Melchior, L., & Sørensen, J. B. (2018) · Oncotarget · doi:10.18632/oncotarget.25490 · Cited by 42
Han, F., Huang, D., Huang, X., Wang, W., Yang, S., & Chen, S. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15402 · Cited by 42
Identification and Characterization of Oncogenic SOS1 Mutations in Lung Adenocarcinoma
Cai, D., Choi, P. S., Gelbard, M., & Meyerson, M. (2019) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-18-0316 · Cited by 41
Self-citationPIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38
Gao, Y., Päivinen, P., Tripathi, S., Domènech-Moreno, E., Wong, I. P. L., Vaahtomeri, K., Nagaraj, A. S., Talwelkar, S. S., Foretz, M., Verschuren, E. W., et al. (2022) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2049 · Cited by 40
NetBID2 provides comprehensive hidden driver analysis
Dong, X., Ding, L., Thrasher, A., Wang, X., Liu, J., Pan, Q., Rash, J., Dhungana, Y., Yang, X., Risch, I., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38335-6 · Cited by 37
Self-citationNf1 loss promotes Kras-driven lung adenocarcinoma and results in Psat1-mediated glutamate dependence
Wang, X., Min, S., Liu, H., Wu, N., Liu, X., Wang, T., Li, W., Shen, Y., Wang, H., Qian, Z., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201809856 · Cited by 33
“One patient-derived KRAS -mutant/ TP53 -WT/ NF1 -WT cell line (PDK) and two KRAS -mutant/ TP53 -WT/ NF1 -mutant (PDKN1 and PDKN2) cell lines were derived from the human LUAD tumors identified above according to a previously described methodology (Niederst et al , 2015).”
The Current Understanding Of Asbestos-Induced Epigenetic Changes Associated With Lung Cancer
Cheng, Y. Y., Rath, E. M., Linton, A., Yuen, M. L., Takahashi, K., & Lee, K. (2020) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s186843 · Cited by 31
O’Farrell, H., Harbourne, B., Kurlawala, Z., Inoue, Y., Nagelberg, A. L., Martinez, V. D., Lu, D., Oh, M. H., Coe, B. P., Thu, K. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.12.004 · Cited by 23
LKB1 drives stasis and C/EBP-mediated reprogramming to an alveolar type II fate in lung cancer
Murray, C. W., Brady, J. J., Han, M., Cai, H., Tsai, M. K., Pierce, S. E., Cheng, R., Demeter, J., Feldser, D. M., Jackson, P. K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28619-8 · Cited by 22
Bidimensional linked matrix factorization for pan-omics pan-cancer analysis
Lock, E. F., Park, J. Y., & Hoadley, K. A. (2022) · The Annals of Applied Statistics · doi:10.1214/21-aoas1495 · Cited by 19
Koenig, M. J., Agana, B. A., Kaufman, J. M., Sharpnack, M. F., Wang, W. Z., Weigel, C., Navarro, F. C. P., Amann, J. M., Cacciato, N., Arasada, R. R., et al. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-3199 · Cited by 18
“TeXPderived LINE1 RPKM values for TCGA LUAD samples were compared using a Wilcoxon rank-sum test with continuity correction Human cell lines and LKB1 constructs All human cell lines were acquired fromATCC.”
BackgroundResultInfluentialPoirier, A., Gagné, A., Laflamme, P., Marcoux, M., Orain, M., Plante, S., Joubert, D., Joubert, P., & Laplante, M. (2021) · Cancers · doi:10.3390/cancers13164136 · Cited by 15
The complex role of NRF2 in cancer: A genomic view
Praslicka, B. J., Kerins, M. J., & Ooi, A. (2016) · Current Opinion in Toxicology · doi:10.1016/j.cotox.2016.09.003 · Cited by 14
Synergy of EGFR and AURKA Inhibitors in KRAS -mutated Non–small Cell Lung Cancers
Bagnyukova, T., Egleston, B. L., Pavlov, V. A., Serebriiskii, I. G., Golemis, E. A., & Borghaei, H. (2024) · Cancer Research Communications · doi:10.1158/2767-9764.crc-23-0482 · Cited by 14
Role of SWI/SNF chromatin remodeling genes in lung cancer development
Monterde, B., & Varela, I. (2022) · Biochemical Society Transactions · doi:10.1042/bst20211084 · Cited by 13
Cao, H., Jia, C., Li, Z., Yang, H., Fang, R., Zhang, Y., & Cui, Y. (2024) · British Journal of Cancer · doi:10.1038/s41416-024-02587-w · Cited by 12
Suaiti, L., Sullivan, T. B., Rieger-Christ, K. M., Servais, E. L., Suzuki, K., & Burks, E. J. (2023) · Clinical Lung Cancer · doi:10.1016/j.cllc.2022.12.006 · Cited by 11
LKB1 regulates JNK-dependent stress signaling and apoptotic dependency of KRAS-mutant lung cancers
Li, C., Syed, M. U., Nimbalkar, A., Shen, Y., Vieira, M. D., Fraser, C., Inde, Z., Qin, X., Ouyang, J., Kreuzer, J., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-58753-y · Cited by 11
WANG, C., SU, H., YANG, L., & HUANG, K. (2017) · Biocomputing 2017 · doi:10.1142/9789813207813_0009 · Cited by 9
A phase II trial of mTORC1/2 inhibition in STK11 deficient non small cell lung cancer
Middleton, G., Robbins, H. L., Fletcher, P., Savage, J., Mehmi, M., Summers, Y., Greystoke, A., Steele, N., Popat, S., Jain, P., et al. (2025) · npj Precision Oncology · doi:10.1038/s41698-025-00838-4 · Cited by 7
Tamiya, M., Kunimasa, K., Nishino, K., Matsumoto, S., Kawachi, H., Kuno, K., Inoue, T., Kuhara, H., Imamura, F., Goto, K., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-020-00966-7 · Cited by 5
Lin, S., & Jia, P. (2024) · GigaScience · doi:10.1093/gigascience/giae108 · Cited by 4
An integrated model for predicting KRAS dependency
(2023) · doi:10.1371/journal.pcbi.1011095 · Cited by 3
Machine Learning Applications in Lung Cancer Diagnosis, Treatment and Prognosis
Li, Y., Wu, X., Yang, P., Jiang, G., & Luo, Y. (2022) · arXiv · doi:10.48550/arxiv.2203.02794 · Cited by 2
“Another study [56] utilized the inception-V3 network [57] to classify whether the tissue was lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), or normal from H&E-stained histopathology whole-slide images.”
InfluentialBian, S., Bian, H., Koyama, H., Kompaniiets, D., Tse, W., Shah, M. V., Al-Kali, A., Miron, A., Liu, B., & Liu, S. (2026) · International Journal of Biological Sciences · doi:10.7150/ijbs.131687
“Among these genetic aberrations, TP53 is one of the most mutated genes [5, 6] and the most extensively investigated prognostic marker in NSCLC. TP53 mutations appear in over 50% of patients with NSCLC [7-9], who have poorer clinical outcomes and shorter survival time than those without mutations…”
Metadata
- Authors
- The Cancer Genome Atlas Research Network
- Venue
- Nature
- Published
- 2014-07-09
- Volume
- 511
- Issue
- 7511
- Pages
- 543-550
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- PMC
- PMC4231481
- OpenAlex
- W2180481128
- Cited by
- 5,732
- References
- 42
- Citations by year
- 2026: 314 · 2025: 415 · 2024: 428 · 2023: 523 · 2022: 547 · 2021: 614 · 2020: 613 · 2019: 495 · 2018: 478 · 2017: 516 · 2016: 427 · 2015: 312 · 2014: 47
- FWCI
- 347.50
- Type
- journal article
- Language
- en
- Update notices
- Open access
- hybrid
- doi.org
- Licence
- cc-by-nc-sa
- creativecommons.org/licenses/by-nc-sa/3.0/ (tdm)
- creativecommons.org/licenses/by-nc-sa/3.0/ (vor)
- Locations
- Nature (publishedVersion, cc-by-nc-sa)
- PubMed (publishedVersion)
- Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
- PubMed Central (acceptedVersion, cc-by-nc-sa)
- SERVAL (Université de Lausanne) (acceptedVersion, cc-by-nc-sa)
- eScholarship (California Digital Library) (submittedVersion)
- IRIS (submittedVersion, cc-by-nc-sa)
- eSpace (Curtin University) (submittedVersion)
- Scholarworks@UNIST (Ulsan National Institute of Science and Technology) (submittedVersion)
- Funders
- Howard Hughes Medical Institute
- National Institutes of Health (UL1TR000005)
- National Human Genome Research Institute (U54HG003067, U54HG003079, U54HG003273, R01HG006272)
- National Cancer Institute (U24CA126554, U24CA143882, U24CA143843, U24CA143840, U24CA126546, CA143883, U24CA143858, K08CA137153, U24CA126543, U24CA144025, U24CA126563, U24CA143866, U24CA143883, CA143840, U24 CA137153, U24CA143845, U24CA126544, U24CA180951, U24CA143867, U24CA143848, U24CA143799, U24CA126551, U24CA143835, U24CA126561, P30CA177558, P30CA008748, P30CA016672, P30CA006973)
- National Institute of General Medical Sciences (T32GM007753)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
- Keywords
- lung adenocarcinoma, somatic mutations, RIT1, MGA, MYC amplification, EGFR mutation, RBM10, neurofibromatosis type 1, MET, ERBB2, MET exon 14 skipping, splicing alterations, MAPK signaling, PI3K signaling, DNA methylation, microRNA, transcriptome, proteome, molecular classification, carcinogenesis
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Female, Humans, Lung Neoplasms, Male, Mutation, Oncogenes, Sex Factors, Gene Expression Regulation, Neoplastic, Gene Dosage, Cell Cycle Proteins, Genomics, Molecular Typing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.